Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | TOURMALINE-MM4: oral ixazomib maintenance for myeloma

Meletios Dimopoulos • 3 Jun 2020
EHA 2020
Multiple Myeloma Ixazomib
TOURMALINE-MM4

Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses TOURMALINE-MM4 (NCT02312258), a Phase III trial of oral ixazomib maintenance therapy in participants with newly diagnosed multiple myeloma not treated with stem cell transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Meletios Dimopoulos

Linvoseltamab with daratumumab or isatuximab in heavily pretreated patients with multiple myeloma 1:19
Linvoseltamab with daratumumab or isatuximab in heavily pretreated patients with multiple myeloma
Meletios Dimopoulos • 7 Dec 2025
Long-term follow-up of ECWM-1: dexamethasone, rituximab, and cyclophosphamide +/- bortezomib in WM 0:51
Long-term follow-up of ECWM-1: dexamethasone, rituximab, and cyclophosphamide +/- bortezomib in WM
Meletios Dimopoulos • 7 Dec 2025
Long-term follow-up of belantamab mafodotin plus pomalidomide and dexamethasone in myeloma: DREAMM-8 1:07
Long-term follow-up of belantamab mafodotin plus pomalidomide and dexamethasone in myeloma: DREAMM-8
Meletios Dimopoulos • 7 Dec 2025
MagnetisMM-6 trial cohort G data: assessing EDR in transplant-ineligible newly diagnosed myeloma 2:08
MagnetisMM-6 trial cohort G data: assessing EDR in transplant-ineligible newly diagnosed myeloma
Meletios Dimopoulos • 12 Jun 2025

Related Videos

Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis 2:35
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
Alexander Lesokhin • 8 Dec 2025
Integrated approaches to improve prognosis prediction in multiple myeloma 2:32
Integrated approaches to improve prognosis prediction in multiple myeloma
Claudio Cerchione • 6 Dec 2025
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals